???? Enlivex (Nasdaq: ENLV): Watch the Investor Webinar Replay on Promising Allocetra™ Osteoarthritis Data!
Missed the live event? Catch the replay of Enlivex’s latest investor webinar, where Executive Chairman Shai Novak and CEO Oren Hershkovitz, Ph.D., shared positive interim six-month data from the Phase I/II Allocetra™ trial in knee osteoarthritis.
???? Key Takeaways:
✔️ 47% pain reduction (P=0.0001) and 46% joint function improvement at six months
✔️ 83% responder rate, highlighting durability of the treatment
✔️ No serious adverse events, reinforcing a strong safety profile
???? Why It Matters: With millions suffering from osteoarthritis and no disease-modifying treatments available, Allocetra™ could be a breakthrough therapy in this high-demand market.
???? Watch the Full Webinar Replay Now: https://youtu.be/Q91dYg9_ct0
#ENLV #BiotechInvesting #Osteoarthritis #ClinicalTrials #HealthcareInnovation #Investors
Missed the live event? Catch the replay of Enlivex’s latest investor webinar, where Executive Chairman Shai Novak and CEO Oren Hershkovitz, Ph.D., shared positive interim six-month data from the Phase I/II Allocetra™ trial in knee osteoarthritis.
???? Key Takeaways:
✔️ 47% pain reduction (P=0.0001) and 46% joint function improvement at six months
✔️ 83% responder rate, highlighting durability of the treatment
✔️ No serious adverse events, reinforcing a strong safety profile
???? Why It Matters: With millions suffering from osteoarthritis and no disease-modifying treatments available, Allocetra™ could be a breakthrough therapy in this high-demand market.
???? Watch the Full Webinar Replay Now: https://youtu.be/Q91dYg9_ct0
#ENLV #BiotechInvesting #Osteoarthritis #ClinicalTrials #HealthcareInnovation #Investors
Commentaires